Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Provectus Pharma
(OP:
PVCT
)
0.1590
+0.0061 (+3.99%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
153,743
Open
0.1529
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1529
Today's Range
0.1522 - 0.1689
52wk Range
0.0560 - 0.2245
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PVCT Stock Earnings: Provectus Reported Results for Q1 2024
May 14, 2024
Provectus just reported results for the first quarter of 2024.
Via
InvestorPlace
PVCT Stock Earnings: Provectus Reported Results for Q4 2023
March 28, 2024
Provectus just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
+51.72%
+51.72%
1 Month
-18.17%
-18.17%
3 Month
-21.44%
-21.44%
6 Month
+54.37%
+54.37%
1 Year
+33.61%
+33.61%
More News
Read More
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
January 17, 2023
Via
Benzinga
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
December 12, 2022
From
Provectus Biopharmaceuticals Inc.
Via
GlobeNewswire
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
December 01, 2022
From
Provectus Biopharmaceuticals Inc.
Via
GlobeNewswire
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
November 10, 2022
From
Provectus Biopharmaceuticals Inc.
Via
GlobeNewswire
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
November 02, 2022
From
Provectus Biopharmaceuticals Inc.
Via
GlobeNewswire
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
October 25, 2022
From
Provectus Biopharmaceuticals Inc.
Via
GlobeNewswire
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
September 29, 2022
From
Provectus Biopharmaceuticals Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.